AI-generated · cited to primary sources · not investment advice · How we research
Apollo Hospitals
Our verdict on Apollo Hospitals isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The company successfully operationalized a 30-bed facility in Defence Colony, Delhi, which is part of the AHLL network expansion. (1 met across 1 tracked commitment)
“To add 4,400 capacity beds ~3,600 census beds over the next 5 years”
The composite scheme involving the amalgamation of Keimed and the restructuring of the pharmacy business is underway to achieve the 100% ownership structure. (1 in progress across 1 tracked commitment)
“Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros”
See the full cited Management analysis of Apollo Hospitals
How durable is the business?
Average Length of Stay (ALOS) dropped by 7% due to the adoption of new technologies like robotics and digital command centers, which improves bed turnover and efficiency. (1 expanding)
“ALOS has dropped by 7%... the use of new technologies, whether it is the cardiac where we have minimally resistant or robotics. So, this is really driving down ALOS and allowing us to discharge patients much faster.”
The core hospital business continues to expand through increased clinical intensity and pricing power, with revenue growing 14% and EBITDA margins improving from 24.1% to 24.8%. Growth was driven by an 11% increase in Average Revenue Per Inpatient (ARPP). (1 expanding)
“6 Metros Operating Beds 4,581 Occupancy 71% ARPP -IP 208,477 ROCE 31%”
See the full cited Business Model analysis of Apollo Hospitals
Where does growth come from?
Apollo has formalized a massive expansion plan to add 4,372 total beds (3,577 census beds) over the next 5 years, targeting a total capacity of ~13,000 census beds. This is a significant acceleration in planned capacity addition compared to previous maintenance cycles. (2 accelerating, 2 steady across 4 signals, 1 leading indicator)
“To add 4,400 capacity beds ~3,600 census beds over the next 5 years... Total Project Cost of ~Rs 8,200crs”
Average Revenue per Inpatient (ARPP) grew by 9% YoY to ₹172,282, driven by an 8% improvement in price and case mix. This indicates a steady upward trajectory in clinical complexity and pricing power. (1 steady, 1 accelerating across 2 signals)
“Average Revenue per In patient grew by 11% to Rs 180,917 in Q3FY26”
See the full cited Future Growth analysis of Apollo Hospitals
What could break the thesis?
The expansion risk remains high but stable as the company maintains its target to add ~3,577 census beds over the next 5 years with a total project cost of ~₹ 7,603 crs. The balance to be spent is ₹ 5,400 crs. (2 stable, 2 intensifying, 1 high-severity)
“Total Project Cost of ~₹ 8,200crs with Balance to be spent of ~₹5,400crs. To add 4,400 capacity beds ~3,600 census beds over the next 5 years”
The risk is intensifying as the restructuring has entered a more complex phase with the approval of a 'Composite Scheme' involving the demerger of pharmacy distribution and amalgamation of Keimed. (5 intensifying)
“Consol Gross Debt 28,614”
See the full cited Risk analysis of Apollo Hospitals
Read the full thesis on Apollo Hospitals
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.